Insiders Trades
Gentian Diagnostics ASA Stock: price and insider trades · Norway
No insider purchase over the last 90 days. The latest was filed 02 May 2024.
Gentian Diagnostics ASA: what insiders have been doing
Gentian Diagnostics ASA is a Health Care company. Its directors and officers file their transactions with Oslo Børs. In the past year (18 October 2025 to 18 October 2026), 7 filings came from 6 insiders.
Not one of the filings records a straightforward purchase or sale on the market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
For context, the typical company on the same exchange (median of 257 companies) published 4 filings over the same period, against 7 filings here. Our records for Gentian Diagnostics ASA go back to 2021, with 5 purchases and 2 sales on the open market in total.
No insider has bought Gentian Diagnostics ASA shares on the open market in the past twelve months.
Elsewhere in the same sector, our signals recently picked up insider purchases at MAIA Biotechnology, Inc. and Cooper Companies, Inc. This summary is built from Oslo Børs disclosures alone and does not predict where the share price will go.
Insider Decl.
23
Thresholds
n/a
Buy Volume
€703,164
5 ops. · all time
Sell Volume
€5M
2 ops. · all time
Who traded when
BuySaleOslo Rule Book II.1 sale
Since the insiders bought
- +25.4%Entry NOK 39.40 · Close at T+365 NOK 49.40
- -1.6%Entry NOK 44.00 · Close at T+365 NOK 43.30
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Fundamental score
Ranked 11,381 of 24,148 companies
53.0
score / 100
Value47
Quality59
FCF yld5.4%
Earn yld2.3%
EV/EBITDA17.2x
ROE-4.4%
Gross mgn56%
Net mgn7.5%
Debt/EBITDA0.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
NOK 37.90
Analyst consensus
1 analysts1.00/5
NOK 60.00Target NOK 60.00(+58%)NOK 60.00
Income statement
RevenueNOK 176.5M
Gross profitNOK 98.2M56% margin
EBITDANOK 35.5M20% margin
Net incomeNOK 13.3M-4.6% margin
Valuation
PER (forward)14.7x
P/Book3.2x
Beta0.45
Balance sheet & cash
Market capNOK 585.9M
Total debtNOK 23M
Free Cash FlowNOK 31.8M
Debt / Equity9%
Profitability & ownership
ROE-4.4%
ROA6.3%
% insiders44.6%
% institutions40.1%
Last declaration on 29 May 2026
Declarations23 total
5,000 shares@ NOK 35.850.030% mcap33.9% of flowOptionXOSLOSLO:674916
@ €2.9147OptionXOSLOSLO:668095
3,115 shares@ NOK 40.00100.0% of flowOptionXOSLOSLO:666196
2,500 shares@ NOK 40.0018.0% of flowOptionXOSLOSLO:665812
3,000 shares@ NOK 40.00100.0% of flowOptionXOSLOSLO:665709
5,000 shares@ NOK 54.8648.1% of flowOptionXOSLOSLO:658078
101,848 shares@ NOK 51.50100.0% of flowShareXOSLOSLO:645715
5,000 shares@ NOK 46.200.3% of flowShareXOSLOSLO:643162
1,228,502 shares@ NOK 46.5066.5% of flowShareXOSLOSLO:640237
614,251 shares@ NOK 46.5033.2% of flowShareXOSLOSLO:640236
@ €5.3446OptionXOSLOSLO:634851
180,000 shares@ NOK 38.0705100.0% of flowShareXOSLOSLO:617577
Canonical exit: 30 Jul 2024 (T+90)
OptionXOSLOSLO:604901
5,000 sharesOptionXOSLOSLO:598195
13,800 shares@ NOK 47.50100.0% of flowShareXOSLOSLO:589733
OptionXOSLOSLO:578263
20,000 shares@ NOK 43.5072.5% of flowShareXOSLOSLO:569996
Canonical exit: 27 Nov 2022 (T+90)
2,166 shares@ NOK 44.538.1% of flowShareXOSLOSLO:569842
Canonical exit: 24 Nov 2022 (T+90)
800 shares@ NOK 43.002.9% of flowShareXOSLOSLO:569751
Canonical exit: 23 Nov 2022 (T+90)
3,636 shares@ NOK 55.9416.5% of flowShareXOSLOSLO:555151
Canonical exit: 29 May 2022 (T+90)
OptionXOSLOSLO:548211
100,000 shares@ NOK 67.2174100.0% of flowShareXOSLOSLO:540725
23 of 23 declarations
About Gentian Diagnostics ASA
Gentian Diagnostics ASA is a company focused on developing innovative diagnostic tests for medical laboratories. It is listed on the Oslo Stock Exchange.
